Generic Name

Exenatide

Brand Names
Bydureon BCise, Byetta
FDA approval date: December 10, 2014
Classification: GLP-1 Receptor Agonist
Form: Injection

What is Bydureon BCise (Exenatide)?

Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Should not be used for the treatment of type 1 diabetes. Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Limitations of Use Exenatide injection is not indicated for use in patients with type 1 diabetes. Exenatide injection contains exenatide and should not be used with other products containing the active ingredient exenatide. Exenatide injection has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions.

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information